key: cord-0971762-x08zciir
authors: Fukuda, Yosuke; Homma, Tetsuya; Inoue, Hideki; Goto, Yuiko; Sato, Yoko; Ikeda, Hitoshi; Onitsuka, Chisato; Sato, Hiroki; Akimoto, Kaho; Ebato, Takaya; Suganuma, Hiromitsu; Kawahara, Tomoko; Mikuni, Hatsuko; Uchida, Yoshitaka; Suzuki, Shintaro; Tanaka, Akihiko; Sagara, Hironori
title: Serum IL-28A/IFN-λ2 is linked to disease severity of COVID-19
date: 2022-03-31
journal: Sci Rep
DOI: 10.1038/s41598-022-09544-8
sha: 024db98e8b98ccb94c51a214dfea393401e58741
doc_id: 971762
cord_uid: x08zciir

Type III interferons (IFNs) play an important role in respiratory viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to determine whether the expression of serum type III IFNs predicted disease severity among patients with the coronavirus disease (COVID-19). A retrospective cohort study was conducted of patients admitted to a single hospital between March 21, 2020, and March 31, 2021. Patients were divided into mild to moderate I (MM) and moderate II to severe (MS) groups based on the COVID-19 severity classification developed by the Japanese Ministry of Health, Labor and Welfare. A total of 257 patients were included in the analysis. Human interleukin-28A (IL-28A/IFN-λ2) expression was significantly lower, and interleukin (IL)-6 expression was significantly higher in the MS group than in the MM group (both p < 0.001). In addition, IL-28A/IFN-λ2 was statistically significantly inversely correlated with the time from disease onset to negative SARS-CoV-2 PCR results (p = 0.049). Multivariable logistic regression analysis showed that IL-28A/IFN-λ2 was an independent predictor of disease severity (p = 0.021). The low expression of IL-28A/IFN-λ2 may serve as a serum biomarker that predicts the severity of COVID-19, possibly through the mechanism of delayed viral elimination.

The interferon (IFN) response is a key immune response in respiratory viral infections. Among the IFNs, type III IFNs (IFN-λ) have recently attracted much attention for their antiviral activity. An experimental mouse model of influenza virus infection showed that viral infection resulted in a greater increase in IFN-λ than in IFN-α 1 . Mordstein et al. 2 reported that mice deficient in both IFN I and IFN III receptors were more susceptible to viral respiratory infections than mice deficient only in IFN I receptors. These previous reports suggest that IFN-λ may play a central role in airway epithelial cells.

It has been reported that IFN-λ inhibits viral replication in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but not in severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection 3 . Unlike SARS-CoV-1, SARS-CoV-2 infection induces a large number of IFN-stimulated genes (ISGs), which exert direct antiviral effects 4 . In addition, a previous pilot study showed that serum IFN-λ expression was decreased among patients with severe coronavirus disease (COVID-19) compared to those with mild COVID-19 5 , which is in line with previous reports 6 . Lucas et al. 7 reported that IFN-λ is one of the cytokines characterizing severe COVID-19 in their cluster analysis of cytokines for moderate-to-severe COVID-19. These findings suggest that IFN-λ may have a valuable function in However, it is not clear whether the expression of IFNs in COVID-19, especially serum IFNs, which can be measured noninvasively, is a predictor of disease severity. Therefore, in this study, we investigated whether the expression of serum IFN-λ was an independent predictor of disease severity among patients with COVID-19, in combination with previously reported predictors of COVID-19 disease severity.

Patient characteristics are shown in Table 1 . The median age of patients was 55 years, 32% were aged 65 years or older. Patients in the MS group accounted for 29% of the total population. Figure 1 shows a comparison of serum cytokines between the MM and MS groups in all patients at admission. The expression of IL-6 was significantly higher, and the expression of IL-28A/IFN-λ2 was significantly lower, in the MS group than in the MM group (Fig. 1 , both p < 0.001). In addition, the MS group had a higher white blood cell count, and higher lactate dehydrogenase, C-reactive protein, ferritin, Kreb von den Lungen-6 levels, and a lower lymphocyte count than the MM group ( Supplementary Fig. 1 ). www.nature.com/scientificreports/ To examine factors affecting serum cytokines, we performed a multiple regression analysis of serum IL-6 and IL-28A/IFN-λ2, which were significantly differentially expressed depending on the severity of the disease in this study ( Fig. 0.1 ). Multiple linear regression analysis showed that the presence of immunodeficiency was a factor that significantly affected serum IL-6 and age was a factor that significantly affected IL-28A/IFN-λ2 (Tables 2 and 3) .

Serum cytokine distribution was examined using the kernel smoothing method to clarify the relationship between serum cytokines and age ( Supplementary Fig. 2) . The results showed that IFN-α and IL-28A/IFN-λ2 were bimodally distributed. We divided the entire patient population into two groups, younger (≤ 65 years) and elderly (> 65 years), and performed cytokine analysis (Fig. 2 ). In the younger population, IL-6 was significantly higher (p = 0.001), and IL-28A/IFN-λ2 was significantly lower (p = 0.022) in the MS group. In the elderly population, only IL-6 was significantly higher in the MS group than in the MM group (Fig. 2 , p < 0.001). Figure 3 shows the correlation between serum cytokines and the time from disease onset to becoming PCR negative. IL-28A/IFN-λ2 and IFN-28B/IFN-λ3 were inversely correlated with the time from disease onset to becoming PCR negative (p = 0.049, p = 0.032, respectively). Although we examined cytokines and time from onset to becoming negative PCR in each MM and MS group, there was no statistically significant correlation ( Supplementary Fig. 3) .

A multiple regression analysis of markers of disease severity using known risk factors [8] [9] [10] [11] , IL-6, and IL-28A/ IFN-λ2 revealed that IL-28A/IFN-λ2 was an independent predictor of severe disease (p = 0.021, Table 4 ). Age older than 65 years, sex, and obesity were also independent predictors of severe disease. 

This study revealed that the expression of IL-28A/IFN-λ2 in serum was low in patients with severe COVID-19. This result was consistent with the results of a previous study 5 . Furthermore, we showed that serum IL-28A/IFN-λ2 was an independent factor for COVID-19 severity and that serum IL-28A/IFN-λ2 was inversely correlated with the time to becoming PCR negative. The importance of IFN-λ has been demonstrated in viral infections, such as influenza. The addition of IL-29/ IFN-λ1 to alveolar type II epithelial cells induces antiviral genes such as myxovirus resistance protein 1,2'-5'-oligoadenylate synthetase 1, and ISG56 12 . Experiments using a mouse model of influenza A virus infection of the upper and lower respiratory tracts showed that IFN-λ exerted antiviral effects for a more extended period than IFN-α 13 . Moreover, it was reported that in the serum of patients infected with Puumala hantavirus, IFN-λ expression was reduced by about 9% in the acute phase compared with the recovery phase 14 . In vitro studies comparing SARS-CoV-1 and SARS-CoV-2 showed that although viral replication was higher in SARS-CoV-2 infection than in SARS-CoV-1 infection, the expression of IFN-λ1,2,3 in lung tissue was not different between SARS-CoV-2 and controls 15 . The expression of serum IFN-λ was maintained in children regardless of the severity of COVID-19 16 , suggesting that the disease severity is relatively lower in children than in adults. These findings suggest that IFN-λ may be important in preventing severe disease. In the present study, multivariable analysis revealed that serum IL-28A/IFN-λ2 was an independent predictor of disease severity in COVID-19, after controlling for severity factors found in several previous studies. Collectively, serum IFN-λ, especially IL-28A/IFN-λ2, may be a biomarker of disease severity in COVID-19.

The present study also revealed that IL-29/IFN-λ1 and IL-28A/IFN-λ2 were weakly, but certainly statistically inversely correlated with the time until becoming SARS-CoV-2 PCR became negative. Experiments using human alveolar epithelium have found that IFN-λ is induced by SARS-CoV-2 infection and persistently inhibits SARS-CoV-2 replication for 7 days 17 . IFN-β and IFN-λ1 have been shown to inhibit SARS-CoV-2 replication in a dose-dependent manner 18 . In contrast to type I IFNs, expressed in the liver, spleen, brain, and other parenchymal organs, type III IFNs are expressed predominantly in the airway epithelium and gastrointestinal epithelium 2, 19 . In these epithelia, plasmacytoid dendritic cells control viral infections by releasing IFN-λ. It has been found that patients with COVID-19 experience a prolonged reduction in dendritic cell function, which is more pronounced in severely ill patients 20 . In older patients, activation of factors that control signal transduction, including PI3K signaling, is reduced, and it is possible that virus excretion may be delayed due to the reduced function of plasmacytoid dendritic cells [21] [22] [23] . Another study showed that prostaglandin D2 receptor 1 promotes viral elimination by increasing the production of IL-28A 24 . This study did not reveal the mechanism by which IL-28A/IFN-λ2 and IL-28B/IFN-λ3 were inversely correlated with the time to PCR negativity in COVID-19, so further investigation is needed.

One of the main strengths of this study is that it demonstrated that IL-28A/IFN-λ2, a type III IFN, was an independent predictor of COVID-19 severity. Identifying factors that predict disease severity is important for defining treatment targets. Although it is unclear how type III interferon acts on COVID-19, one possible explanation is that type III IFNS including IL-28A/IFN-λ2 may contribute to the prevention of severe disease by promoting viral shedding.

However, there were some limitations to the study. First, this was a single-center study conducted over a relatively short period of time. The number of patients is also not sufficient to analyze all confounding factors reported so far. Second, we did not analyze changes in the serum cytokine concentrations over time. It is important to determine whether serum IFN recovers after treatment. A study comparing serum cytokines in COVID-19 and seasonal influenza found that serum levels of IFN-λ1 and IFN-α remained low for at least 3 weeks in patients with COVID-19 25 . Third, it is unclear why patients with severe disease had a greater reduction in serum IL-28A/ IFN-λ2 than other types of type III IFN-λ. Similar to our results, it has been report that IL-28A/IFN-λ2 plays an essential role in COVID-19 pathogenesis 26 . Some previous reports have shown that IL-29/IFN-λ1 and IL-28B/ IFN-λ3 are markers of COVID-19 disease activity 25, 27 . Fourth, we could not demonstrate the downregulation of type III IFNs in severe COVID-19 in the elderly (Supplementary Fig. 1) . The reasons could be due to small number of participants or the total amount of expression of type III IFNs are generally less among elderly population.

In summary, this study showed that serum IL-28A/IFN-λ2 is linked to viral excretion of SARS-CoV-2, and its expression level may be associated with the severity of COVID-19. As serum IL-28A/IFN-λ2 is decreased in Table 4 . Risk factors associated with COVID-19 severity based on multivariable logistic regression analysis. BMI body mass index, CI confidence interval, IFN interferon, IL interleukin, OR odds ratio. www.nature.com/scientificreports/ severe COVID-19, IL-28A/IFN-λ2 supplementation may be an appropriate treatment for COVID-19. A randomized placebo-controlled trial showed that a single subcutaneous injection of peginterferon lambda safely and significantly shortened viral shedding duration compared to placebo 28 . Although, various drugs that control the cytokine storm, such as corticosteroids, anti-IL-6 antibodies, and Janus kinase inhibitors, are thought to be effective against severe COVID-19, some patients with severe disease do not recover with these drugs alone or in combination. Therefore, further studies focusing on serum IFNs are needed to develop novel treatments for COVID-19.

This observational study was conducted from March 21, 2020 to March 31, 2021 at Showa University Hospital in Tokyo, Japan. We included 257 patients over 16 years of age who had confirmed the diagnosis of COVID-19 based on a positive polymerase chain reaction (PCR) test using a nasal swab. Based on the COVID-19 severity classification developed by the Ministry of Health, Labor and Welfare 29 , we separated the patients into mild-moderate I (MM) and moderate II-severe (MS) groups. We reviewed the medical records and collected the following data: age, sex, body mass index, comorbidities, and blood test results on the first day of hospitalization. All data were fully anonymized before they were accessed. Additionally, we measured the following serum cytokines and chemokines: interleukin (IL)-6, interferon (IFN)-α, IFN-β, IL-29/IFN-λ1, IL-28A/IFN-λ2, and IL-28B/IFN-λ3. The serum concentrations of cytokines and chemokines were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, USA). The ELISAs were performed according to the manufacturer's instructions. A negative PCR for SARS-CoV-2 was defined as two consecutive Ct values above 30.

Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and JMP version 15 (SAS Institute, Minato-ku, Tokyo, Japan). All data were presented as the median (interquartile range) or the frequency (percentage), as appropriate. The validity of the normal distribution was assessed using the Shapiro-Wilk test. Fisher's exact test and the Mann-Whitney U test were used to assess the statistical significance of differences between categorical variables and continuous variables, respectively. Correlations between pairs of continuous variables were analyzed using Pearson's correlation coefficient. We conducted a multivariate logistic regression analysis to evaluate risk factors for COVID-19 severity. Independent variables included potential risk factors based on previous reports [8] [9] [10] [11] and serum IL-28A/IFN-λ2. In addition, we estimated the variance inflation factors for the variables and confirmed that there was no multicollinearity to prove the validity of these parameters. To analyze factors affecting serum cytokines, specifically IL-28A/ IFN-λ2, multiple linear regression analysis was performed combining age, gender, obesity status, and history of obesity. ANOVA test was used to confirm the significance of the analysis. We excluded the points that exceeded 1.5 times the upper and lower limits of the interquartile range as outliers. P values less than 0.05 were considered statistically significant.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Showa University Ethics Committee (approval number: 3300). Informed consent was obtained from all patients on the day of admission.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections

Inhibition of SARS-CoV-2 by type I and type III interferons

Heightened innate immune responses in the respiratory tract of COVID-19 patients

Downregulation of type III interferons in patients with severe COVID-19

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-λ1) in response to influenza A infection

IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission

Lambda interferon (IFN-lambda) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

COVID-19 in children: expressions of type I/II/III interferons, TRIM28, SETDB1, and endogenous retroviruses in mild and severe cases

SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

Antiviral activity of Type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2

IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection

Increased reactivity of dendritic cells from aged subjects to self-antigen, the human DNA

Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinasesignaling pathway

Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity

PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-λ production

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Clinical management of patients with COVID-19. A Guide for Front-line Healthcare Workers version 5

We would like to thank Ms. Megumi Matsuda and Mrs. Teru Haba for their assistance with the basic experiments. We thank Editage (www. edita ge. jp) for English language editing.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-09544-8.Correspondence and requests for materials should be addressed to T.H.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.